Raphas Co., Ltd. Logo

Raphas Co., Ltd.

Develops dissolving microneedle patches for cosmetic, medical, and pharmaceutical applications.

214260 | KO

Overview

Corporate Details

ISIN(s):
KR7214260002
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙8로1길 62 라파스, 강서구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Raphas Co., Ltd. is a biotechnology company specializing in the research, development, and manufacturing of its proprietary transdermal delivery platform. The company's core technology is the patented Dissolving Microneedle (DEN), which enables the effective delivery of active ingredients for cosmetic, medical device, and pharmaceutical applications. Raphas develops and mass-produces innovative microarray patches, commercializing its technology through its own cosmetics brand, Acropass, as well as through partnerships. The platform offers solutions for skin care, including wrinkle and whitening treatments, and is being developed for the potential delivery of drugs and vaccines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 2.0 MB
2025-08-14 00:00
Interim / Quarterly Report
[기재정정]반기보고서 (2025.06)
Korean 2.0 MB
2025-07-28 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 11.9 KB
2025-06-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 127.7 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 2.0 MB
2025-04-28 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 11.5 KB
2025-03-26 00:00
AGM Information
정기주주총회결과
Korean 21.1 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 25.8 KB
2025-03-18 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 373.5 KB
2025-03-18 00:00
Proxy Solicitation & Information Statement
[기재정정]의결권대리행사권유참고서류
Korean 361.8 KB
2025-03-18 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 723.2 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 11.9 KB
2025-03-05 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 15.6 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 189.7 KB

Automate Your Workflow. Get a real-time feed of all Raphas Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Raphas Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Raphas Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
Celltrion Pharm Inc. Logo
South Korea
068760
Develops bone grafts, artificial joints, and enzymes for the biopharmaceutical sector.
South Korea
049180
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN
Celularity Inc Logo
Develops off-the-shelf cell therapies from placentas for cancer and aging-related diseases.
United States of America
CELU
Centessa Pharmaceuticals plc Logo
Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.
United States of America
CNTA
Century Therapeutics, Inc. Logo
Developing iPSC-derived, off-the-shelf cell therapies for cancer & autoimmune diseases.
United States of America
IPSC
Cereno Scientific AB Logo
Develops epigenetic therapies for rare cardiovascular and pulmonary diseases.
Sweden
CRNO
CERO THERAPEUTICS HOLDINGS, INC. Logo
Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.
United States of America
CERO
CERUS CORP Logo
Develops pathogen reduction technology to safeguard the global blood supply for healthcare providers.
United States of America
CERS

Talk to a Data Expert

Have a question? We'll get back to you promptly.